To determine the willingness to pay (WTP) of senior managers in the UK National Health Service (NHS) for services to help manage performance concerns with doctors, dentists and pharmacists.

Our methodology provides a useful framework for projecting UK NHS medicines expenditure over the medium term and captures the impacts of existing medicines losing exclusivity and of new medicines being launched onto the market. </AbstractSection> Copyright Springer International Publishing Switzerland 2013

The European Commission's 'Action Plan against the Rising Threats from Antimicrobial Resistance' (COM(2011) 748), which covered the period 2011-2016, aimed to address the problem of antimicrobial resistance (AMR) at the European level using a holistic approach. The Directorate-General for Health...

Medical negligence was estimated to cost the NHS in England £235m in 1996|1997, growing at rate of up to 25% per annum. Yet analysis of NHS accounts suggest that a change in accounting policy has led to growth rates and recurrent expenditure on medical negligence being over estimated. The main...

This article examines performance-based risk-sharing agreements for pharmaceuticals from a theoretical economic perspective. We position these agreements as a form of coverage with evidence development. New performance-based risk sharing could produce a more efficient market equilibrium,...

The Office of Fair Trading (OFT) Report on the UK Pharmaceutical Price Regulation Scheme (PPRS) recommends that when the current five-year PPRS expires in 2010 it be replaced with 'value-based pricing' which involves pre-launch centralised government price setting based on a cost-per-QALY...